Figure 1.
The flowchart of this phase II clinical study.
Initially 62 patients were enrolled into this study, and 2 were excluded. A total of 60 patients underwent 63 CRS+HIPEC procedures. CRS = cytoreductive surgery, HIPEC = hyperthermic intraperitoneal chemotherapy, SC = systemic chemotherapy, PIC = perioperative intraperitoneal chemotherapy.
Table 1.
Major clinico-pathologic characteristics of the 60 patientsa.
Figure 2.
The disease-specific overall survival in patients with CRC PC treated by CRS+HIPEC and adjuvant chemotherapy regimen (a). The statistical significance in overall survival (OS) comparisons of those patients including PCI (b), CC (c) and postoperative adjuvant chemotherapy cycles (d). mo = months, CRC = colorectal cancer, PC = peritoneal carcinomatosis, CRS = cytoreductive surgery, HIPEC = perioperative intraperitoneal chemotherapy, PCI = peritoneal cancer index, CC = completeness of cytoreduction.
Table 2.
Major treatment and follow-up features of long-term survivors (OS >20 months).
Table 3.
Detail data of the patients with SAE # (n = 19, 30.2%).
Table 4.
Analysis of independent factors influencing survival.